Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG Max Jaderberg, President of Isomorphic Labs, speaks to CNBC's Ritika Gupta at London Tech Week to discuss the advancement of AI in medicine Got ...
Isomorphic Labs, an AI drug discovery and development company, raised $2.1 billion in a Series B funding round led by Thrive Capital. The raise was also backed by existing investors Alphabet and GV ...
Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it might bring to the clinic. “We’re aiming to redefine the way we create new ...
May 12 (Reuters) - Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion in its latest funding round led by existing investor Thrive ...
Isomorphic Labs Inc., an Alphabet Inc. unit using artificial intelligence to speed up drug development, is reportedly in talks to raise a new funding round. Sources told Bloomberg today that the ...
Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting pipeline of new medicines.” Isomorphic Labs, the UK-based biotech spinoff of ...
Isomorphic Walk A method for finding allosteric pathways in proteins — the chains of residues that carry signals across a folded protein from one site to another. Built from a fast graph-search engine ...
Nearly two years after Google DeepMind released an updated AlphaFold3 geared at drug discovery, its biopharmaceuticals spin-off, Isomorphic Labs, announced an even more powerful ...
Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results